DDJ Patient Article · As of March 2026 · Explained Simply
How much does a history of periodontitis increase the risk of peri-implantitis and implant loss, and what does this mean for patient selection?
Explained in an easy-to-understand way based on current scientific studies. This article helps you make informed decisions with your dentist.
This article looks at the likely course of a condition and what it may mean for your care.
In Short and Clear
The most important findings at a glance:
- The results are mixed—there are both positive and critical findings.
- The scientific basis is solid, but not all questions have been definitively answered.
- The risk must be presented as a spectrum, not as a binary warning.
- It is not the diagnosis of gum disease (periodontitis) alone that determines implant risk, but whether it is controlled and if the patient participates.
Why is this topic important for you?
You may have heard that there are differing opinions on this topic. This is because science is often more complex than a simple yes or no answer suggests. In this article, we explain what current research actually shows—without overly technical jargon and without leaving out important details.
A history of gum disease (periodontitis) is not an automatic exclusion criterion, but it is also not irrelevant information. The question is how great the actual risk is.
Why is this important for you? Because as a patient, you can make better decisions when you understand the background. This article does not replace a discussion with your dentist, but it gives you the knowledge to ask the right questions.
In research, the most important questions revolve around the following areas: quantifying increased risk, treated versus untreated periodontitis, and implications for treatment planning. In the following sections, we explain what studies say about each of these areas and what that means for your daily life.
What does "Quantifying Increased Risk" mean for me as a patient?
A common patient question is how to weigh quantifying increased risk. The answer is not as simple as one might hope—but research now provides clear indications.
The most solid quantitative scientific evidence comes from a meta-analysis of several studies by Annunziata et al. (2025), which included only prospective long-term observational studies with at least 36 months of follow-up. Fourteen studies (17 articles) were included from 13,761 initial datasets, eight of which showed a low and six showed a moderate risk of bias according to the Newcastle-Ottawa Scale. The meta-analysis found a significantly increased hazard ratio for implant loss of 1.75 for patients with a history of gum disease (periodontitis) (HP) compared to healthy individuals regarding their gums (NHP).
The data on marginal bone loss are particularly informative: HP patients showed a mean bone loss that was 0.41 mm higher. For periimplantitis, the odds ratio was 3.24, while no significant group difference was found for periimplant mucositis. This differentiation is clinically relevant: The risk primarily affects the severe, bone-destructive form of the disease, not mild tissue inflammation.
Ravidà et al. (2024) add a cost factor to this perspective. In their retrospective analysis of 399 adults with over 10 years of follow-up, periodontal therapy was overall cost-effective in preventing tooth extractions and implant replacement. However, heavy current smoking completely eliminated this cost-effectiveness. Former smokers with Grade C gum disease (periodontitis) benefited the most from periodontal therapy, while smoking reduced cost-effectiveness depending on dosage.
The meta-analysis by Monje et al. (2014) focused specifically on generalized aggressive periodontitis (GAgP) and included six non-randomized prospective clinical studies. Survival rates were 83.3 to 100% for GAgP, 96.4 to 100% for chronic gum disease (periodontitis), and 96.9 to 100% for healthy individuals over a mean period of 48 to 72 months. Although the overall risk ratio for survival was not significant (RR 0.96; 95% CI: 0.91–1.01; p = 0.14), the failure rate analysis showed a fourfold increased failure rate for AgP compared to healthy individuals (RR 4.0) and compared to chronic gum disease (periodontitis) (RR 3.97). Mean bone loss was 0.28 mm higher in GAgP than in healthy individuals and 0.43 mm higher than in chronic gum disease (periodontitis).
Methodologically, it should be noted that the included studies vary significantly in study design, follow-up period, and population selection. This heterogeneity limits the comparability of results and explains why pooled effect estimates must be interpreted with caution. Nevertheless, the direction of the effect is consistent across different study types.
For applicability to the German-speaking care context, it is also relevant that a significant portion of the scientific evidence comes from Anglo-American or Scandinavian healthcare systems. Differences in reimbursement structure, treatment culture, and patient access can influence effect sizes without invalidating the core finding.
For the clinical practice, an HR of 1.75 for implant loss means that the risk is relevant but not prohibitively increased. With a baseline implant loss rate of about 2 to 4% over 10 years in healthy populations concerning the gums, this rate rises to an estimated 3.5 to 7% in people with gum disease, which represents an acceptable prognosis for most patients, provided the periodontal condition is controlled.
Conversely, the 6-fold increased risk with Grade C gum disease (periodontitis) (HR 6.16) marks a clinically relevant risk threshold that must be explicitly addressed in patient selection and education. These patients require more intensive follow-up care and transparent counseling regarding the limited prognosis.
In daily practice, this means: The scientific evidence does not provide a one-size-fits-all answer but rather a framework for individualized decisions. Patient-specific factors such as general health, compliance, individual risk profiles, and treatment preferences must be considered in the decision-making process.
What does this mean for you? The risk must be presented as a spectrum, not as a binary warning.
What does this mean for your next dental appointment? The research findings help you better contextualize your dentist's recommendations and ask targeted questions if anything is unclear.
Science has intensively investigated this topic in recent years. Several scientific studies contribute to the current assessment. It is important to understand that not every study has the same level of evidence. Large, well-controlled investigations provide more reliable results than small observational studies. The overall picture derived from these various studies is what we present to you here.
💡 What does this mean for you?
The risk must be presented as a spectrum, not as a binary warning. Discuss with your dentist at your next visit what this specifically means for your situation.
What matters more: Treated or untreated periodontitis?
When it comes to treated versus untreated periodontitis, the research situation is clearer than many people think. Here you will learn what current studies actually show.
The clinically decisive difference lies not in the diagnosis of gum disease (periodontitis), but in the current periodontal status at the time of implantation. Annunziata et al. (2025) show in subgroup analyses that patients with Stage III to IV (severe) periodontitis have a higher risk of implant loss than patients with milder disease, and that implants with rough surfaces show an additionally increased loss risk in smokers.
Monje et al. (2014) emphasize that residual periodontal pockets act as an infection niche for implants and that periodontopathogenic germs are still detectable in the gums of compromised teeth even one year after extraction. The ecological conditions of the oral cavity immediately influence biofilm formation on implants, which explains the mechanistic link between active gum disease (periodontitis) and peri-implantitis risk.
The cost analysis by Ravidà et al. (2024) indirectly confirms the value of periodontal pre-treatment: patients who had the lowest annual costs for periodontal therapy had the highest costs for tooth extractions and implant replacement, suggesting undertreatment. Conversely, periodontal therapy invested in non-smokers and former smokers was cost-effective regarding the avoidance of the need for implants.
Bezerra et al. (2022) reviewed multiple studies on the role of pro-inflammatory gene mutations in peri-implantitis, including studies that analyzed the association between genetic polymorphisms (especially IL-1 and TNF-alpha variants) and peri-implant diseases. Although a trend toward increased peri-implantitis risk with certain polymorphisms was observed, the scientific evidence was heterogeneous and not sufficient to recommend genetic testing as a clinical selection criterion.
Methodologically, it must be noted that the included studies vary significantly in study design, follow-up period, and population selection. This heterogeneity limits the comparability of the results and explains why pooled effect estimates must be interpreted with caution. Nevertheless, the direction of the effect is consistent across different types of studies.
For transferability to the German-speaking care context, it is also relevant that a significant portion of the scientific evidence comes from Anglo-American or Scandinavian healthcare systems. Differences in reimbursement structure, treatment culture, and patient access can influence effect sizes without invalidating the core message.
For clinical practice, this scientific evidence suggests that implant candidacy in individuals with gum disease depends not only on the diagnosis but also on the current control status. Before planning implants, the periodontal condition must be fully assessed, any active gum disease (periodontitis) must be treated, and a stable condition must be documented for at least three to six months.
Modifiable risk factors such as smoking and oral hygiene compliance must be addressed before implantation, as they influence the prognosis more strongly than the historical diagnosis. Smoking cessation should be considered an integral part of implant planning for individuals with gum disease.
In daily practice, this means that the scientific evidence does not provide a one-size-fits-all answer but rather a framework for individualized decisions. Patient-specific factors such as general health, compliance, individual risk profiles, and treatment preferences must be factored into the decision.
What does this mean for you? It is important to state the status precisely, not just the diagnosis.
What does this mean for your next dental visit? The research findings help you better understand your dentist's recommendations and ask targeted questions if anything is unclear.
How do scientists arrive at these conclusions? They don't just evaluate a single study; they look at many studies simultaneously. This allows them to determine whether a result was random or if it is consistently confirmed. In this case, the findings are based on 5 scientific papers from different countries and research groups.
💡 What does this mean for you?
It is important to state the status precisely, not just the diagnosis. Discuss with your dentist at your next visit what this specifically means for your situation.
What does "Consistency in Education" mean for me as a patient?
One point that often causes confusion is consistency in education. However, science has made important progress in recent years.
Quantified risk increases allow for differentiated patient counseling. Annunziata et al. (2025) provide the basis for evidence-based risk stratification: In chronic gum disease (periodontitis) with a controlled status and good compliance, the implant loss risk is moderately higher than that of healthy individuals (HR 1.75). With previously aggressive or Grade C gum disease (periodontitis), the risk increases sixfold, requiring intensive follow-up care and an explicitly more restrictive indication.
Monje et al. (2014) quantify marginal bone loss as an additional prognostic parameter: The weighted mean difference was -0.28 mm for GAgP versus healthy and -0.43 mm for GAgP versus chronic gum disease (periodontitis) over a medium period of 30 months. This accelerated bone loss is an early indicator of implant risk and should be closely monitored during recall appointments.
For education, it is relevant that the differences are real but not dramatic, as long as the gum disease (periodontitis) is controlled. Annunziata et al. (2025) found no significant difference in periimplant mucositis between HP and NHP, suggesting that early inflammatory signs appear evenly, and only the progression to destructive peri-implantitis marks a risk difference.
The factor of smoking significantly potentiates the risk associated with gum disease (periodontitis). Ravidà et al. (2024) show a dose-dependent relationship, indicating that heavy current smokers completely lose the cost-effectiveness of periodontal therapy. For implant consultation, this means that the combination of a history of gum disease (periodontitis) and active smoking represents a particularly critical risk constellation.
Methodologically, it must be noted that the included studies vary significantly in study design, follow-up period, and population selection. This heterogeneity limits the comparability of the results and explains why pooled effect estimates must be interpreted with caution. Nevertheless, the direction of the effect is consistent across different study types.
Furthermore, for applicability to the German-speaking care context, it is relevant that a significant portion of the scientific evidence originates from Anglo-American or Scandinavian healthcare systems. Differences in reimbursement structure, treatment culture, and patient access can influence effect sizes without invalidating the core message.
The patient education should transparently name three risk levels: controlled chronic gum disease (periodontitis) (moderate increased risk), severe or rapidly progressing gum disease (periodontitis) (markedly increased risk), and active or uncontrolled gum disease (periodontitis) (implantation not indicated until stabilization). Modifiable factors such as smoking cessation and compliance should be communicated as having a positive prognostic effect.
Aftercare for individuals with gum disease who have implants must be more closely managed than for healthy gums. A recall interval of three to six months, including systematic assessment of probing depths, bleeding on probing, and radiographic bone level, is indicated.
In daily practice, this means that the scientific evidence does not provide a one-size-fits-all answer but rather a framework for individualized decision-making. Patient-specific factors such as general health, compliance, individual risk profiles, and treatment preferences must be incorporated into the decision.
What does this mean for you? The consultation must name modifiable risk factors.
What does this mean for your next dental visit? The research findings help you better contextualize your dentist's recommendations and ask targeted questions if anything is unclear.
What makes these results reliable? In medical research, the principle is: the more independent studies that reach the same conclusion, the more certain the statement is. The type of study and the number of participants also play an important role. Large controlled studies with many participants provide more reliable results than small surveys.
💡 What does this mean for you?
The consultation must name modifiable risk factors. Discuss with your dentist at your next visit what this specifically means for your situation.
Frequently Asked Questions
Here we answer the questions patients most frequently ask about this topic:
❓ What does "quantifying increased risk" mean for me as a patient?
Patients with treated gum disease (periodontitis) have an increased, but not prohibitive, risk. The risk must be presented as a spectrum, not as a binary warning.
❓ What matters more: treated or untreated periodontitis?
Successfully treated gum disease (periodontitis) significantly lowers the implant risk compared to uncontrolled disease. It is important to specify the status, not just the diagnosis.
❓ What does "implication for patient education" mean for me as a patient?
Informed consent requires a quantified statement of risk. The consultation must name modifiable risk factors.
❓ How certain are the results?
The scientific basis is solid, but not all questions have been definitively answered.
❓ Should I change my behavior based on this information?
Speak with your dentist before making any changes. This article informs you about the current state of research, but every situation is individual. Your dentist knows your personal health status best.
❓ Where can I learn more?
You can find the full professional version of this article, with all study details, on Daily Dental Journal. For personal advice, please consult your dentist.
❓ What is the main takeaway from this article?
A history of gum disease (periodontitis) increases risk but does not rule out implants.
❓ Why are there differing opinions on this topic?
The conflict lies between prognostic pessimism and the clinical reality that many people with gum disease receive successful implant treatment.
🦷 When Should You See Your Dentist?
Schedule an appointment with your dentist if:
- You are unsure if a recommended treatment is appropriate for you
- You have symptoms or notice changes
- You would like a second opinion
- You have questions about the topics described in this article
- It has been more than a year since your last dental visit
Important: This article does not replace a dental visit. It helps you go into the conversation informed.
What You Can Do Yourself
Here are concrete steps you can take as a patient:
The Most Important Takeaway in One Sentence
It is not the periodontal disease (periodontitis) diagnosis alone that determines implant risk, but whether it is controlled and if the patient participates.
Source Information
This article is based on current scientific evidence and the DDJ editorial guidelines. All statements are supported by studies and presented in a way that is easy for patients to understand.
The content was prepared by the DDJ editorial team for patients. Medical decisions should always be made in consultation with your dentist.
Date: March 2026 · Language: American English (en-US) · Target Audience: Patients and interested laypersons